1065482-56-5 Usage
Uses
Used in Pharmaceutical Industry:
2-(Bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline is used as a potential pharmaceutical compound for its unique chemical structure, which may offer novel therapeutic properties and reactivity. Further research and testing are required to explore its potential applications in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(Bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline is used as a potential active ingredient in the development of new pesticides or herbicides. Its unique chemical structure may provide novel modes of action and selectivity against target pests or weeds.
Used in Material Science:
2-(Bromomethyl)-3-(2-chlorophenyl)-5-(trifluoromethyl)quinoxaline is used in material science for its potential applications in the development of new materials with unique properties. Its chemical structure and reactivity may contribute to the creation of advanced materials for various applications, such as sensors, catalysts, or functional coatings.
Check Digit Verification of cas no
The CAS Registry Mumber 1065482-56-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,5,4,8 and 2 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1065482-56:
(9*1)+(8*0)+(7*6)+(6*5)+(5*4)+(4*8)+(3*2)+(2*5)+(1*6)=155
155 % 10 = 5
So 1065482-56-5 is a valid CAS Registry Number.
1065482-56-5Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AND THEIR USES
-
, (2008/12/04)
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.
